Sprint Bioscience AB (publ) announced that the Board has appointed Jessica Martinsson as acting CEO. Jessica Martinsson, who has held the position of operational manager, succeeds Anders Aberg, who has chosen to leave his post after 10 years as CEO. Anders Aberg leaves the position as CEO on June 11 and Jessica Martinsson will take up the position of acting CEO at that time. Anders Aberg retains his shareholding and will remains as senior adviser to the company but will not have an operational role.